INTRODUCTION
Bronchioloalveolar carcinoma (BAC) is a subset of pulmonary adenocarcinoma with characteristic clinical (e.g. bronchorrhea, intrapulmonary shunting) [1] [2] [3] [4] , radiographic 5, 6 , epidemiologic 1, 2, 4 , and histopathologic features 7, 8 . In a recent study analyzing data from the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of BAC is reported to be 3-4% of all non-small-cell lung cancer (NSCLC) 4 . While the incidence of adenocarcinoma has risen significantly from 1979 to 1998, the incidence of BAC has risen only slightly 4 . Women comprised slightly more than half of all BAC cases compared to only about 38% of all NSCLC cases, and the one-year survivorship of BAC (64.9%) was significantly better than NSCLC (37.5%) 4 . However, determining the epidemiology of BAC has been problematic, and estimates of the incidence of this Previous reports on the epidemiology of BAC 1, 2 were performed using data prior to 1999, when the widely accepted definition of BAC from the revised and updated WHO Histological Classification of Tumors was released -on May 28, 1999 8 . Since it had been shown that patients with solitary, non-invasive BAC tumors measuring less than 2.0 cm could be cured 10 , WHO restricted the definition of BAC to non-invasive tumors 8 .
By this definition BAC is an adenocarcinoma with a pure bronchioloalveolar growth pattern, without evidence of stromal, vascular, or pleural invasion 8 -although BAC may still exhibit multifocal involvement via diffuse alveolar spread, and metastatic disease. 5 This definition is much more restrictive than the one previously used by many pathologists and the WHO. For example, in the past, adenocarcinoma with an extensive BAC component would have been classified as BAC.
In the present study, our primary aim is to determine if survival for BAC patients has been affected since the revised 1999 WHO classification system was released, using a large epidemiologic, continuously updated database of cancer distribution in three Southern California counties.
PATIENTS AND METHODS

This was a retrospective study involving analysis of data from the Cancer Surveillance
Programs of Orange County, Imperial County, and San Diego County, California (CSPOC/SANDIOCC databases, covering an area with an estimated population of 6.2 million). The CSPOC/SANDIOCC was developed in collaboration with the California Cancer Registry to serve as a model for regional, population-based cancer registries and to contribute to statewide cancer incidence reporting, as described previously 11 .
Demographic and Clinical Data
Recorded data included demographic information (age, gender, ethnicity, and 
Ethical Considerations
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RESULTS
Demographics
Data on 11,969 incident cases of NSCLC were analyzed. The mean age for the entire group was 68.3 years +/-0.1 standard error (S.E.) ( Table 1 ). The majority of patients were Caucasians (80.4%), followed by Hispanics (8.3%), Asians (7.8%), AfricanAmericans (3.2%), and Others (including Native Americans -0.3%); 54.1% were male.
The vast majority of patients had a history of smoking tobacco, and only 9.7% were never-smokers (Table 1 ). More than half of the patients in this study (51.9%) had metastatic disease at presentation (Table 1) . Adenocarcinoma (n=6720) was the predominant NSCLC histologic subtype (56.2%), followed by squamous cell carcinoma (29.6%), large cell carcinoma (9.0%), and BAC (5.2%) ( Table 1) .
Demographic Comparisons of BAC to other types of NSCLC
The mean age at diagnosis was similar for BAC (68.8 years +/-0.4 SE) and non-BAC NSCLC patients (68.3 years +/-0.1 SE; P = 0.23) ( Table 2) . A statistically higher proportion of females was detected in the BAC patients when compared to the non-BAC NSCLC patients (59.3% vs. 45.2%; P < 0.0001) ( Table 2) . A greater proportion of neversmokers was found in the BAC group (23.0%) compared to patients with non-BAC NSCLC subtypes (9.0%; P < 0.0001) ( 19.6% were localized, 27.0% regional spread, and 53.4% metastatic (P < 0.0001) ( Table 2) .
BAC Pathologic Specimens
Pathologic diagnosis of BAC was confirmed in 623 out of 626 BAC cases (99.5%). In total, 47 cases (7.5%) were evaluated from cytologic specimens alone, 145 cases (23.3%) were evaluated from biopsy specimens, 62 cases (10.0%) were evaluated from wedge resection or segmentectomy specimens, 350 cases (56.2%) were evaluated from lobectomy specimens, and 19 cases (3.0%) were evaluated from pneumonectomy specimens.
Survival Analyses
Survival analyses for each of the NSCLC histologic subtypes are presented in Fig 1.
Significant differences in OS were detected: BAC had a median OS = 42 months [95% confidence intervals (C.I.) 32-51], the median OS for squamous cell carcinoma was 10 months (95% C.I. 10-11), the median OS for adenocarcinoma was 9 months (95% C.I.
9-10), and large cell carcinoma exhibited the poorest median OS at 6 months (95% C.I.
5-6) (p<0.0001). Due to the observed similar survival trends for the non-BAC NSCLC subtypes, these data were combined together to compare survival of this group to the 10 observed survival in BAC patients. Patients with BAC were found to have a significantly prolonged median OS (42 months, 95% C.I. 32-51) compared to the median OS of non-BAC NSCLC patients (9 months, 95% C.I. 9-10; P < 0.0001). One-year (69.6% vs.
42.4%), two-year (58.1% vs. 27.3%), and five-year (41.4% vs. 14.5%) survival rates were improved for BAC compared to non-BAC NSCLC cases.
Univariate survival analyses for BAC and non-BAC NSCLC by stage at presentation were performed. Median OS for BAC was statistically improved over non-BAC NSCLC for localized stage (>98 months vs. 47 months; P < 0.0001), regional spread (47 months vs. 16 months; P < 0.0001), and metastatic disease at presentation (10 months vs. 5 months; P < 0.0001).
On multivariate analyses for the overall group (n=11,969), factors associated with C.I. 1.09-1.20; P < 0.0001), and never-smoker status (HR for ever-smoker status =1.09, 95% C.I. 1.00-1.18; P = 0.045) ( Table 3) .
Survival for Advanced Stage BAC
Subset survival analysis was performed on patients with advanced BAC due to intrapulmonary disease or distant metastasis. The following patients were identified and included in this analysis: 12 patients with separate BAC tumors within the same lobe (but without distant metastasis, i.e. T4M0, stage IIIb), 67 patients with BAC tumors in a separate lobe (i.e. M1, stage IV due to intrapulmonary disease, without distant metastasis), and 59 patients with distant metastasis of BAC. Among these three groups of advanced BAC patients (n=138), significant differences in survival were noted 11 (p<0.0001) (Fig 2) . For the patients with T4M0 disease, 2 underwent wedge resection or segmentectomy (17%), 7 had lobectomy performed (58%); three patients were not treated surgically (25%). Median OS for this group of T4M0 patients was not reached at >50 months follow-up duration, one-year survival rate was 82%, and two-year survival rate was 82%. For the patients with M1 disease from intrapulmonary spread, 10 patients underwent wedge resection or segmentectomy (15%), 7 patients underwent lobectomy (10%), and 8 patients underwent pneumonectomy (12%); 42 patients (63%) were not treated surgically. Median OS for this group was 13 months (95% C.I. 7-24), one-year survival rate was 51%, and two-year survival rate was 36%. Patients with stage IV BAC due to distant metastasis had the poorest survival characteristics, with a median OS of 5 months (95% C.I. 4-9), 27% one-year survival rate, and 8% two-year survival rate. Fortysix of these patients (80%) were not treated surgically, 6 had wedge resection or segmentectomy (10%), and 6 underwent lobectomy (10%). Excluding T4M0 patients from the above survival analysis, the observed difference in median OS for BAC patients with M1 disease due to intrapulmonary spread (13 months) compared to patients with distant BAC (5 months) was statistically significant (p=0.0004).
Epidemiology of BAC and non-BAC NSCLC before and after May 1999
The incidence of BAC was 5.0% of all NSCLCs before May 1999, and 5.5% of all NSCLCs after May 1999. There was a statistically significant greater proportion of females in the group of BAC patients diagnosed after May 1999 than from the period January 1995-May 1999 (63.0% vs. 55.3%; P = 0.048, Table 4 ). There were no differences in the ethnicity of BAC patients (P = 0.25) between the two periods. There was a trend towards a higher proportion of never-smokers in the BAC group diagnosed after May 1999 compared to those diagnosed in the period January 1995-May 1999, however this was not statistically significant (P = 0.07). In the non-BAC NSCLC group 12 ( were statistically significant (P = 0.001).
As stated above, nearly one-half of all BAC patients before and after May 1999
had localized stage at presentation, yet significant differences in survival and cause of death were noted for localized stage BAC. In an attempt to elucidate the overall effects of these differences, lung cancer-specific survival analyses were conducted after censoring all data beyond 53 months, to allow for equal follow-up duration before and (Fig 4) . Accordingly, 1-year and 2-year lung cancer-specific survival rates were improved in those patients diagnosed from June 1999-December 2003 compared to those patients diagnosed from January 1995-May 1999 (Fig 4) .
DISCUSSION
In this population-based analysis, we have shown that BAC exhibits significant epidemiologic differences from the other non-BAC NSCLCs. We have shown that BAC patients when compared to non-BAC NSCLC patients comprise a group with more females, and more never-smokers. BAC patients also have earlier stage at presentation, improved survival for each stage at presentation, superior overall survival, and greater survival after adjustment for stage, gender, and smoking status when compared to non-BAC NSCLC patients. (Table 4) . Thus, despite the slightly greater proportion of BAC patients with metastatic disease at presentation detected after May 1999, who will eventually die of lung cancer, the improved overall survival for this large group of local stage at presentation BAC patients contributes greatly to the overall survival benefit of all BAC patients diagnosed after May 1999 (Fig 3) . Additionally, these observed differences in the proportion of deaths due to lung cancer by stage at presentation contribute to the large increase in lung cancer-specific survival (Fig 4) for BAC cases diagnosed after May 1999 when compared to BAC cases diagnosed prior to May 1999.
We hypothesize that these evolving epidemiologic trends for BAC are due to the revised 1999 WHO classification itself. The overall survival differences, and lung cancer-specific survival differences detected here may be due to adherence to the 1999 WHO classification system by pathologists, excluding many patients with pleural involvement, or adenocarcinoma subtype from the diagnosis of BAC. The lack of survival benefit for non-BAC NSCLC cases diagnosed after May 1999 compared to those diagnosed before May 1999, as depicted in Fig 3, resected multifocal lung BAC (including 10 patients with pathologically confirmed pIIIb or pIV disease) revealed a 64% five-year survival rate. These two studies together suggest that patients with multicentric BAC indeed benefit from surgery. In addition to the above studies, our epidemiologic analysis reveals that patients with stage IV multicentric BAC (due to intrapulmonary spread) have a significantly better prognosis than patients with stage IV BAC due to distant metastasis, and supports the modification of subsequent classification systems to reflect these differences. . Females, never-smokers, and patients with adenocarcinoma or BAC were found by others to have improved responsiveness to the oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib 15, [19] [20] [21] . Somatic mutations in lung tumors at exons 18 through 21 of EGFR-1 were detected in patients responsive to gefitinib 22, 23 and erlotinib 24 . These were comprised of a group of lung tumors classified as adenocarcinoma, pure BAC, or adenocarcinoma with BAC features.
Analyses in many of these studies included cases of BAC using previous WHO 18 definitions (i.e. adenocarcinoma with BAC features would be labeled as BAC) instead of using strict adherence to the revised 1999 WHO definition 15, 22, 25 . With the potential impact of the revised 1999 WHO classification on survival in patients with BAC demonstrated in this study, and given the heterogeneity of responses of the various EGFR tyrosine kinase inhibitors in patients with NSCLC, we believe that strict adherence to these revised definitions will help unify results from subsequent studies on BAC, and define a subset of lung cancer with similar mutational profiles and distinct clinical presentation.
In general our results are consistent with the majority of reports showing at least a modest survival benefit observed for NSCLC patients who were never-smokers [26] [27] [28] [29] [30] .
One possible explanation for why the effect of smoking on survival in our study is so modest is likely related to the fact that 2265 cases (i.e. 18.9% of our total study population) had no recorded smoking history. Subset analyses of these excluded patients reveal a significant decrease in median survival when compared to either the ever-smokers, or never-smokers (data not shown). Review of the text files for these cases indicated that many of these patients died soon after diagnosis during their initial hospital admission, often they did not have a primary oncologist, and limited historical data was available for these cases. Since a large proportion of ever-smokers likely exists in this poor-prognostic group, the detrimental effects of smoking on survival in our study may be blunted. However, with available information on smoking status for 81.1%
of the population of interest in this study, we believe the analyses incorporating data on smoking status here represent an important aspect of this study. Integrating smoking history into the epidemiology of lung cancer is of utmost importance, and yet such information can be difficult to obtain in population-based studies. For example, currently the SEER database does not contain information related to smoking history. 2-year Survival 60% 76%
